What is PHIGENIX?
Phigenix, Inc. is a prominent entity in personalized healthcare, focusing on the development of advanced cancer diagnostics and targeted therapies. The company's technological innovations include diagnostic tests for prostate and breast cancer, designed to identify patient suitability for specific treatments. Furthermore, Phigenix is at the forefront of pioneering new methods for early cancer detection and is developing a cancer vaccine utilizing Human Beta Defensin-1 mRNA to target cancer cells. Its strong foundation is built upon a substantial intellectual property portfolio, comprising over 100 patents and pending applications in personalized medicine.
How much funding has PHIGENIX raised?
PHIGENIX has raised a total of $856K across 2 funding rounds:
Private Equity
$842K
Debt
$14K
Private Equity (2014): $842K, investors not publicly disclosed
Debt (2021): $14K led by PPP
Key Investors in PHIGENIX
PPP
Public-Private Partnership
What's next for PHIGENIX?
The recent infusion of moderate growth capital, as part of a major enterprise-level funding initiative, positions Phigenix for accelerated scaling and further research and development. This strategic backing is expected to fuel the expansion of its diagnostic platforms and the advancement of its novel cancer vaccine technology. The company's robust patent portfolio suggests a strong commitment to innovation and market leadership, indicating a trajectory focused on translating its cutting-edge research into impactful clinical solutions and solidifying its position in the competitive personalized medicine landscape.
See full PHIGENIX company page
